Harvard Bioscience Statistics
Harvard Bioscience (HBI0) Stock Statistics & Valuation Metrics
Total Valuation
Harvard Bioscience has a market cap or net worth of EUR 38.23M. The enterprise value is EUR 75.56M.
- Market Cap
- EUR 38.23M
- Enterprise Value
- EUR 75.56M
Share Statistics
Harvard Bioscience has 4,573,080 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 4,573,080
- Owned by Insiders
- 9.35%
- Owned by Institutions
- 34.74%
Financial Efficiency
Harvard Bioscience’s return on equity (ROE) is -4.13 and return on invested capital (ROIC) is -1.04%.
- Return on Equity (ROE)
- -4.13
- Return on Assets (ROA)
- -0.71
- Return on Invested Capital (ROIC)
- -1.04%
- Return on Capital Employed (ROCE)
- -0.01
- Revenue Per Employee
- 263.87K
- Profits Per Employee
- -172.87K
- Employee Count
- 328
- Asset Turnover
- 1.08
- Inventory Turnover
- 1.95
Valuation Ratios
The current PE Ratio of Harvard Bioscience is -3.57. Harvard Bioscience’s PEG ratio is -0.08.
- PE Ratio
- -3.57
- PS Ratio
- 0.48
- PB Ratio
- 8.39
- Price to FCF
- -12.92
- Price to Operating Cash Flow
- -62.71
- PEG Ratio
- -0.08
Income Statement
In the last 12 months, Harvard Bioscience had revenue of 86.55M and earned -56.70M in profits. Earnings per share was -12.80.
- Revenue
- 86.55M
- Gross Profit
- 45.88M
- Operating Income
- -629.00K
- Pretax Income
- -57.39M
- Net Income
- -56.70M
- EBITDA
- -46.52M
- Earnings Per Share (EPS)
- -12.80
Cash Flow
In the last 12 months, operating cash flow was -683.00K and capital expenditures -2.64M, giving a free cash flow of -3.32M billion.
- Operating Cash Flow
- -683.00K
- Free Cash Flow
- -3.32M
- Free Cash Flow per Share
- -0.73
Dividends & Yields
Harvard Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -7.67%
- Earnings Yield
- -27.31%
Stock Price Statistics
- Beta
- 1.38
- 52-Week Price Change
- -16.05%
- 50-Day Moving Average
- 4.08
- 200-Day Moving Average
- 4.15
- Relative Strength Index (RSI)
- 38.50
- Average Volume (3m)
- ―
Important Dates
Harvard Bioscience upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Mar 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Harvard Bioscience as a current ratio of 2.20, with Debt / Equity ratio of 322.39%
- Current Ratio
- 2.20
- Quick Ratio
- 1.25
- Debt to Market Cap
- 1.26
- Net Debt to EBITDA
- -0.77
- Interest Coverage Ratio
- -0.13
Taxes
In the past 12 months, Harvard Bioscience has paid -686.00K in taxes.
- Income Tax
- -686.00K
- Effective Tax Rate
- 0.01
Enterprise Valuation
Harvard Bioscience EV to EBITDA ratio is -21.66, with an EV/FCF ratio of -24.91.
- EV to Sales
- 0.93
- EV to EBITDA
- -21.66
- EV to Free Cash Flow
- -24.91
- EV to Operating Cash Flow
- -121.18
Balance Sheet
Harvard Bioscience has EUR 4.86M in cash and marketable securities with EUR 44.29M in debt, giving a net cash position of -EUR 39.44M billion.
- Cash & Marketable Securities
- EUR 4.86M
- Total Debt
- EUR 44.29M
- Net Cash
- -EUR 39.44M
- Net Cash Per Share
- -EUR 8.62
- Tangible Book Value Per Share
- -EUR 2.27
Margins
Gross margin is 57.43%, with operating margin of -0.36%, and net profit margin of -13.20%.
- Gross Margin
- 57.43%
- Operating Margin
- -0.36%
- Pretax Margin
- -13.53%
- Net Profit Margin
- -13.20%
- EBITDA Margin
- -4.27%
- EBIT Margin
- -8.83%
Scores
- Smart Score
- 2
- AI Score
- ―
